Discovery Partners International, Inc. and Bruker AXS Inc. Announce New Bench Top Protein Crystallization System
28 February 2005 - 11:00PM
PR Newswire (US)
Discovery Partners International, Inc. and Bruker AXS Inc. Announce
New Bench Top Protein Crystallization System SAN DIEGO, Feb. 28
/PRNewswire-FirstCall/ -- Discovery Partners International, Inc.
(NASDAQ:DPII) and Bruker AXS Inc., a subsidiary of Bruker
BioSciences Corporation (NASDAQ:BRKR), together announced the
launch of a bench top version of their popular CRYSTAL FARM(TM)
product for high-throughput protein crystallization at the 2005
Pittsburgh Conference in Orlando. The new CRYSTAL FARM CF-150
employs the same technology as the CF-400 model in a smaller
footprint. The Crystal Farm products have become a market leader in
protein crystallization and imaging for the drug discovery and high
throughput crystallography community. The Crystal Farm is a fully
integrated web-based incubation and imaging system used for protein
crystallization screening and optimization. By providing
high-throughput protein crystallization automation, Crystal Farm
addresses the critical quest for high-speed structure-based drug
discovery and design. The bench top system combines capacity for up
to 15,000 simultaneous experimental conditions, with DPI's patent
pending "Cool Flash" imaging technology, and includes a web-browser
based interface that controls all system functions either locally
or remotely, including priority-based image scheduling, viewing and
scoring. Experimental results stored in a SQL database can be
easily mined for monitoring and optimizing crystallization
experiments. "The strategic partnership between Discovery Partners
and Bruker AXS has allowed us to provide powerful crystallization
and X-ray diffraction solutions to the drug discovery and
structural biology communities," said John Lillig, CTO & Vice
President of Discovery Partners International. "The technological
leadership of the Crystal Farm, together with Bruker's expertise
and marketing presence in X-ray crystallography, has allowed the
Crystal Farm to establish a strong position in this dynamic new
market." "The Crystal Farm product has become very popular in
large, high-throughput labs, where it produces better quality
crystals, more quickly than traditional manual crystallization
techniques. We are excited to introduce the bench top model which
will make this technology accessible for innovative new
applications in smaller-scale laboratories as well," said Dr. Roger
Durst, Vice President of R&D and Global Crystallography
Business Manager of Bruker AXS. Pittcon 2005, the 56th Pittsburgh
Conference and Exposition on Analytical Chemistry and Applied
Spectroscopy, is being held from February 27 through March 4 in the
Orange County Convention Center. The product introduced here will
be exhibited at the Bruker booth #3176. About Discovery Partners
Discovery Partners International, Inc. is a leader in drug
discovery collaborations. DPI offers integrated services, products,
and systems that span the drug discovery continuum, including
target characterization, targeted and screening-library design and
synthesis, high throughput and high content screening, lead
generation and optimization, gene expression analysis, and protein
crystallization. DPI has actively contributed to dozens of drug
discovery collaborations, working on many of the most promising new
biological target areas for the biotech and pharmaceutical
industries. Discovery Partners International is headquartered in
San Diego, California and has operations in the United States and
Europe. For more information on Discovery Partners International,
Inc., please visit the Company's website at
http://www.discoverypartners.com/. Statements in this press release
with respect to Discovery Partners or its business or products that
are not strictly historical are "forward-looking" statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and involve a high degree of risk and uncertainty. Discovery
Partners' actual results may differ materially from those projected
in the forward looking statements due to risks and uncertainties
that exist in Discovery Partners' operations, development efforts
and business environment, including risks relating to customer
adoption of Discovery Partners products (including Crystal Farm
products), the ability of Discovery Partners and Bruker AXS to
achieve the goals of their strategic alliance, Discovery Partners'
ability to establish and maintain strategic alliances with third
parties, the trend toward consolidation of the pharmaceutical
industry, technological advances by competitors, and other risks
and uncertainties more fully described in Discovery Partners'
annual report on Form 10-K for the year ended December 31, 2003 as
filed with the Securities and Exchange Commission and Discovery
Partners' other SEC reports. About Bruker Biosciences Bruker
Biosciences Corporation, headquartered in Billerica, Massachusetts,
is the publicly traded parent company of Bruker AXS Inc. and Bruker
Daltonics Inc. Bruker AXS is a leading developer and provider of
life science and advanced materials research tools based on X-ray
technology. Bruker Daltonics is a leading developer and provider of
innovative life science tools based on mass spectrometry. For more
information, please visit http://www.bruker-biosciences.com/ Any
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to Bruker Biosciences'
reorganization strategies, integration risks, failure of
conditions, technological approaches, product development, market
acceptance, cost and pricing of Bruker Biosciences' products,
changes in governmental regulations, capital spending and
government funding policies, FDA and other regulatory approvals to
the extent applicable, competition, the intellectual property of
others, patent protection and litigation. These and other factors
are identified and described in more detail in our filings with the
SEC, including, without limitation, our annual report on Form 10-K
for the year ended December 31, 2003, our most recent quarterly
reports on Form 10-Q and our current reports on Form 8-K. We
disclaim any intent or obligation to update these forward-looking
statements. DATASOURCE: Discovery Partners International, Inc.
CONTACT: John Lillig, CTO & Vice President, +1-858-228-4113, or
Craig Kussman, CFO, +1-858-228-4113, both of Discovery Partners
International, ; or Roger Durst, Vice President of R&D,
+1-608-276-3066, or Michael Willett, P.R. & Investor Relations
Officer, +1-978-663-3660 ext. 1411, , both of Bruker AXS Inc. Web
site: http://www.bruker-biosciences.com/ Web site:
http://www.discoverypartners.com/
Copyright
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024